egiramlon 10mg/10mg tvrdá tobolka
egis pharmaceuticals plc, budapešť array - 9374 ramipril; 12990 amlodipin-besilÁt - tvrdá tobolka - 10mg/10mg - ramipril a amlodipin
egiramlon 10mg/5mg tvrdá tobolka
egis pharmaceuticals plc, budapešť array - 9374 ramipril; 12990 amlodipin-besilÁt - tvrdá tobolka - 10mg/5mg - ramipril a amlodipin
egiramlon 5mg/10mg tvrdá tobolka
egis pharmaceuticals plc, budapešť array - 9374 ramipril; 12990 amlodipin-besilÁt - tvrdá tobolka - 5mg/10mg - ramipril a amlodipin
egiramlon 5mg/5mg tvrdá tobolka
egis pharmaceuticals plc, budapešť array - 9374 ramipril; 12990 amlodipin-besilÁt - tvrdá tobolka - 5mg/5mg - ramipril a amlodipin
darzalex
janssen-cilag international n.v. - daratumumab - mnohočetný myelom - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. v kombinaci s přípravkem bortezomib, thalidomid a dexametazon pro léčbu dospělých pacientů s nově diagnostikovaným mnohočetným myelomem, kteří nejsou způsobilí pro autologní transplantaci kmenových buněk. v kombinaci s lenalidomidem a dexamethasonem, nebo bortezomibu a dexametazonu, k léčbě dospělých pacientů s mnohočetným myelomem, kteří absolvovali alespoň jednu předchozí terapii. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. jako monoterapie k léčbě dospělých pacientů s relabujícím a refrakterním mnohočetným myelomem, jejichž předchozí léčba zahrnovala proteazomový inhibitor a imunomodulační činidlo, a kteří prokázali progresi onemocnění při poslední terapii. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.
jyseleca
gilead sciences ireland uc, galapagos nv - filgotinib maleate - artritida, revmatoidní - imunosupresiva - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
tritace 10mg tableta
sanofi s.r.o., praha array - 9374 ramipril - tableta - 10mg - ramipril
tritace 1,25mg tableta
sanofi s.r.o., praha array - 9374 ramipril - tableta - 1,25mg - ramipril
tritace 2,5mg tableta
sanofi s.r.o., praha array - 9374 ramipril - tableta - 2,5mg - ramipril
tritace 5mg tableta
sanofi s.r.o., praha array - 9374 ramipril - tableta - 5mg - ramipril